Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1915-1925

  Villalona Calero, Miguel A ^a   Weiss, Geoffrey R ^a   Burris, Howard A ^a   Kraynak, Maura ^a   Rodrigues, Gladys ^a   Drengler, Ronald L ^a   Eckhardt, S Gail ^a   Reigner, Bruno ^a   Moczygemba, Judy ^a   Burger, Hans Ulrich ^a   Griffin, Tom ^a   Von Hoff, Daniel D ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR;

EID: 0033040540     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1915     Document Type: Article

References (29)

1. Ishitsuka H, Miwa M, Ishikawa T, et al: Capecitabine: An orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res 36:407, 1995 (abstr 2426)
2. Budman D, Meropol N, Reigner B, et al: Preliminary studies of a novel oral fluoropyrimidinecarbamate: Capecitabine. J Clin Oncol 16:1795-1802, 1998
3. Bollag W, Hartmann H: Tumor inhibitory effects of a new fluorouracil derivative: 5-Deoxy-5-fluorouridine. Eur J Cancer 16:427-432, 1980
4. Hartmann H, Bollag W: 5′-Deoxy-5-fluorouridine: A new antineoplastic pyrimidine antimetabolite. J Suisse Med 110:1078-1080, 1980
5. Kono A, Hara Y, Sugata S, et al: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31:175-178, 1983
6. Takebayashi Y, Yamada K, Miyadera K, et al: The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer 32A: 1227-1232, 1996
7. Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110-1117, 1996
8. Tanaka Y, Eda H, Fujimoto K, et al: Anticachectic activity of 5'-DFUR in a murine tumour cachexia model, colon 26 adenocarcinoma. Cancer Res 50:4528-4532, 1990
9. Ishikawa T, Ura M, Yamamoto T, et al: Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5′-DFUR. Int J Cancer 61:516-521, 1995
10. Bajetta E, Colleoni M, Di Bartolomeo M, et al: Doxifluridine and leucovorin: An oral treatment combination in advanced colorectal cancer. J Clin Oncol 13:2613-2619, 1995
11. Di Bartolomeo M, Bajetta E, Somma L, et al: Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 53:54-57, 1996
12. Alberto P: Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. Ann Oncol 4:423-425, 1993
13. Ishikawa T, Utoh M, Sawada N, et al: Xeloda (capecitabine): An orally available tumor-selective fluoropyrimidine carbamate. Proc Am Soc Clin Oncol 16:208a, 1997 (abstr 727)
14. Schuller J, Cassidy J. Reigner B, et al: Tumor selectivity of Xeloda in colorectal cancer patients. Proc Am Soc Clin Oncol 16:227a, 1997 (abstr 797)
15. Mackean M, Planting A, Twelves C, et al: A phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985, 1998
16. Taguchi T, Ishitani, K, Saitoh K, et al: A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann Oncol 7:87, 1996 (suppl 1) (abstr 299)
17. Eda H, Fujimoto K, Watanabe S, et al: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32:333-338, 1993
18. Eda H, Fujimoto K, Watanabe S, et al: Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 84:341-347, 1993
19. Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019, 1998
20. Bogdan C, Ding A: Taxol, a microtubule stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leuk Biol 52:119-121, 1992
21. Rowinsky E, Donehower R: Paclitaxel (Taxol). N Engl J Med 332:1004-1114, 1995
22. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
23. Royer I, Alvinerie P, Armand J, et al: Paclitaxel metabolites in human plasma and urine: Identification of 6 alpha-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom 9:495-502, 1995
24. Reigner B, Verweij J, Dirix L, et al: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4:941-948, 1998
25. Gibaldi M, Perrier D: Noncompartmental analysis based on statistical moment theory, in Gibaldi M, Perrier D (eds): Pharmacokinetics (ed 2). New York, Marcel Dekker, 1992, pp 409-417
26. Eisenhauer E, ten Bokkel Huinink W, Swenerton K, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
27. Cresteil T, Monsarrat B, Alvinerie P, et al: Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isoenzymes involved in its biotransformation. Cancer Res 54:386-392, 1994
28. Klaassen U, Wilke H, Harstrick A, et al: Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: Results of a phase II study. Ann Oncol 9:45-50, 1998
29. Bokemeyer C, Lampe CS, Clemens M, et al: A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8:396-399, 1997